KR20230134472A - 방사성 핵종 복합체를 위한 안정한 제제 - Google Patents

방사성 핵종 복합체를 위한 안정한 제제 Download PDF

Info

Publication number
KR20230134472A
KR20230134472A KR1020237021396A KR20237021396A KR20230134472A KR 20230134472 A KR20230134472 A KR 20230134472A KR 1020237021396 A KR1020237021396 A KR 1020237021396A KR 20237021396 A KR20237021396 A KR 20237021396A KR 20230134472 A KR20230134472 A KR 20230134472A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
ascorbic acid
sodium ascorbate
salts
radionuclide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237021396A
Other languages
English (en)
Korean (ko)
Inventor
세바스티안 막스
올리버 라이브
루크 헤아메스
엘레나 마리아 안드레올리
Original Assignee
이테엠 졸루친 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이테엠 졸루친 게엠베하 filed Critical 이테엠 졸루친 게엠베하
Publication of KR20230134472A publication Critical patent/KR20230134472A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020237021396A 2020-11-25 2021-11-24 방사성 핵종 복합체를 위한 안정한 제제 Pending KR20230134472A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2020/083363 2020-11-25
PCT/EP2020/083363 WO2022111800A1 (en) 2020-11-25 2020-11-25 Stable formulations for radionuclide complexes
PCT/EP2021/082812 WO2022112323A1 (en) 2020-11-25 2021-11-24 Stable formulations for radionuclide complexes

Publications (1)

Publication Number Publication Date
KR20230134472A true KR20230134472A (ko) 2023-09-21

Family

ID=73598128

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237021396A Pending KR20230134472A (ko) 2020-11-25 2021-11-24 방사성 핵종 복합체를 위한 안정한 제제

Country Status (8)

Country Link
US (2) US20240374732A1 (https=)
EP (1) EP4251213A1 (https=)
JP (1) JP2023552180A (https=)
KR (1) KR20230134472A (https=)
CN (1) CN116806144A (https=)
AU (1) AU2021388832A1 (https=)
CA (1) CA3171753A1 (https=)
WO (2) WO2022111800A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4178628A4 (en) 2020-07-13 2025-04-02 Point Biopharma, Inc. RADIOPHARMACEUTICALS AND PROCEDURES
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
JP2025505307A (ja) * 2022-03-02 2025-02-21 ポイント・バイオファーマ・インコーポレイテッド 放射性医薬品及び方法
US20250099634A1 (en) 2023-09-25 2025-03-27 Novartis Ag Method of treating cancer
WO2025255398A1 (en) * 2024-06-05 2025-12-11 Ariceum Therapeutics Gmbh Radiopharmaceutical composition and methods
US12343409B1 (en) * 2024-06-05 2025-07-01 Ariceum Therapeutics Gmbh Radiopharmaceutical composition and methods
CN120733077B (zh) * 2025-09-01 2025-12-05 杭州景嘉航生物医药科技有限公司 药物组合物及其制备方法与药物制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5139678B2 (ja) * 2003-07-24 2013-02-06 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
AU2012294639B2 (en) 2011-08-05 2017-10-26 Molecular Insight Pharmaceuticals, Inc. Radiolabeled prostate specific membrane antigen inhibitors
PL2970345T3 (pl) 2013-03-15 2019-12-31 Cancer Targeted Technology Llc Znakowane 18F środki do obrazowania PET ukierunkowane na PSMA
EP2862857A1 (en) 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CA3060143A1 (en) 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
US10756278B2 (en) 2017-07-18 2020-08-25 Purdue Research Foundation In situ thermal control of langmuir-schaefer transfer
US10596278B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof

Also Published As

Publication number Publication date
AU2021388832A1 (en) 2023-06-08
WO2022111800A1 (en) 2022-06-02
JP2023552180A (ja) 2023-12-14
WO2022112323A1 (en) 2022-06-02
US20240374732A1 (en) 2024-11-14
CN116806144A (zh) 2023-09-26
CA3171753A1 (en) 2022-06-02
US12605447B2 (en) 2026-04-21
US20250170243A1 (en) 2025-05-29
EP4251213A1 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
US12605447B2 (en) Stable formulations for radionuclide complexes
KR102934560B1 (ko) 신장 보호 물질로서의 파라-아미노히푸르산(pah)
KR20220063214A (ko) Grpr 길항제의 방사성표지 방법 및 이의 키트
EP4065176B1 (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
CA3171718C (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
RU2842991C1 (ru) Комбинация пара-аминогиппуровой кислоты (паг) и меченных радиоактивным изотопом комплексов, предназначенная для лечения рака
RU2804349C2 (ru) Парааминогиппуровая кислота (паг) как вещество для защиты почек
WO2025218931A1 (en) Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same
HK40078095A (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
HK40078095B (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
RU2787105C2 (ru) Новые пса-связывающие агенты и их применение
HK40065088B (en) Para-aminohippuric acid (pah) as a renal protective substance
HK40065088A (en) Para-aminohippuric acid (pah) as a renal protective substance

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230623

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241017

Comment text: Request for Examination of Application